Cargando…
Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder
Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132446/ https://www.ncbi.nlm.nih.gov/pubmed/30039193 http://dx.doi.org/10.1007/s40291-018-0352-x |
_version_ | 1783354324006469632 |
---|---|
author | Rose, Shannon Niyazov, Dmitriy M. Rossignol, Daniel A. Goldenthal, Michael Kahler, Stephen G. Frye, Richard E. |
author_facet | Rose, Shannon Niyazov, Dmitriy M. Rossignol, Daniel A. Goldenthal, Michael Kahler, Stephen G. Frye, Richard E. |
author_sort | Rose, Shannon |
collection | PubMed |
description | Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and the brains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD. |
format | Online Article Text |
id | pubmed-6132446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-61324462018-09-14 Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder Rose, Shannon Niyazov, Dmitriy M. Rossignol, Daniel A. Goldenthal, Michael Kahler, Stephen G. Frye, Richard E. Mol Diagn Ther Review Article Autism spectrum disorder (ASD) affects ~ 2% of children in the United States. The etiology of ASD likely involves environmental factors triggering physiological abnormalities in genetically sensitive individuals. One of these major physiological abnormalities is mitochondrial dysfunction, which may affect a significant subset of children with ASD. Here we systematically review the literature on human studies of mitochondrial dysfunction related to ASD. Clinical aspects of mitochondrial dysfunction in ASD include unusual neurodevelopmental regression, especially if triggered by an inflammatory event, gastrointestinal symptoms, seizures, motor delays, fatigue and lethargy. Traditional biomarkers of mitochondrial disease are widely reported to be abnormal in ASD, but appear non-specific. Newer biomarkers include buccal cell enzymology, biomarkers of fatty acid metabolism, non-mitochondrial enzyme function, apoptosis markers and mitochondrial antibodies. Many genetic abnormalities are associated with mitochondrial dysfunction in ASD, including chromosomal abnormalities, mitochondrial DNA mutations and large-scale deletions, and mutations in both mitochondrial and non-mitochondrial nuclear genes. Mitochondrial dysfunction has been described in immune and buccal cells, fibroblasts, muscle and gastrointestinal tissue and the brains of individuals with ASD. Several environmental factors, including toxicants, microbiome metabolites and an oxidized microenvironment are shown to modulate mitochondrial function in ASD tissues. Investigations of treatments for mitochondrial dysfunction in ASD are promising but preliminary. The etiology of mitochondrial dysfunction and how to define it in ASD is currently unclear. However, preliminary evidence suggests that the mitochondria may be a fruitful target for treatment and prevention of ASD. Further research is needed to better understand the role of mitochondrial dysfunction in the pathophysiology of ASD. Springer International Publishing 2018-07-23 2018 /pmc/articles/PMC6132446/ /pubmed/30039193 http://dx.doi.org/10.1007/s40291-018-0352-x Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Article Rose, Shannon Niyazov, Dmitriy M. Rossignol, Daniel A. Goldenthal, Michael Kahler, Stephen G. Frye, Richard E. Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title_full | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title_fullStr | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title_full_unstemmed | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title_short | Clinical and Molecular Characteristics of Mitochondrial Dysfunction in Autism Spectrum Disorder |
title_sort | clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132446/ https://www.ncbi.nlm.nih.gov/pubmed/30039193 http://dx.doi.org/10.1007/s40291-018-0352-x |
work_keys_str_mv | AT roseshannon clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder AT niyazovdmitriym clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder AT rossignoldaniela clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder AT goldenthalmichael clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder AT kahlerstepheng clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder AT fryericharde clinicalandmolecularcharacteristicsofmitochondrialdysfunctioninautismspectrumdisorder |